P58682
Gene name |
Tlr8 |
Protein name |
Toll-like receptor 8 |
Names |
CD antigen CD288 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:170744 |
EC number |
|
Protein Class |
|

Descriptions
Autoinhibitory domains (AIDs)
Target domain |
25-824 (LRR domains) |
Relief mechanism |
Cleavage |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure

Activated structure

1 structures for P58682
Entry ID | Method | Resolution | Chain | Position | Source |
---|---|---|---|---|---|
AF-P58682-F1 | Predicted | AlphaFoldDB |
86 variants for P58682
Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
---|---|---|---|---|---|
rs3389594411 | 3 | N>T | No | EVA | |
rs261598459 | 43 | S>A | No | EVA | |
rs3412560393 | 61 | I>L | No | EVA | |
rs3389594385 | 90 | T>N | No | EVA | |
rs223472812 | 119 | S>N | No | EVA | |
rs3389562834 | 122 | N>I | No | EVA | |
rs3389584065 | 125 | V>G | No | EVA | |
rs254214752 | 130 | D>G | No | EVA | |
rs3389584093 | 142 | E>V | No | EVA | |
rs3389540506 | 153 | N>Y | No | EVA | |
rs3389540518 | 178 | Y>F | No | EVA | |
rs3412527999 | 183 | Q>H | No | EVA | |
rs3411255567 | 185 | F>L | No | EVA | |
rs3389576351 | 185 | F>S | No | EVA | |
rs3411366869 | 194 | N>K | No | EVA | |
rs3412642817 | 195 | L>V | No | EVA | |
rs3389491352 | 197 | H>Y | No | EVA | |
rs251795045 | 230 | M>V | No | EVA | |
rs3412945610 | 231 | N>I | No | EVA | |
rs3389577133 | 246 | L>Q | No | EVA | |
rs3412560377 | 251 | N>S | No | EVA | |
rs3389533397 | 262 | C>Y | No | EVA | |
rs3412971008 | 264 | P>A | No | EVA | |
rs3411255525 | 264 | P>R | No | EVA | |
rs3389550767 | 293 | S>F | No | EVA | |
rs236002778 | 303 | E>D | No | EVA | |
rs212847065 | 356 | S>P | No | EVA | |
rs248887741 | 360 | K>M | No | EVA | |
rs1132632384 | 362 | R>C | No | EVA | |
rs1132275155 | 363 | S>F | No | EVA | |
rs243485080 | 366 | K>T | No | EVA | |
rs217020350 | 380 | K>E | No | EVA | |
rs227095799 | 384 | H>P | No | EVA | |
rs246188726 | 384 | H>Y | No | EVA | |
rs255475062 | 387 | S>N | No | EVA | |
rs229052869 | 389 | P>S | No | EVA | |
rs31638088 | 416 | D>N | No | EVA | |
rs3389577109 | 425 | I>K | No | EVA | |
rs3411366898 | 429 | L>* | No | EVA | |
rs3411255539 | 430 | D>H | No | EVA | |
rs3389592360 | 432 | T>I | No | EVA | |
rs3389578741 | 444 | P>H | No | EVA | |
rs3412806505 | 459 | Y>* | No | EVA | |
rs3389592384 | 469 | Q>* | No | EVA | |
rs3389586920 | 469 | Q>L | No | EVA | |
rs31637312 | 488 | G>E | No | EVA | |
rs220899481 | 509 | T>S | No | EVA | |
rs257785264 | 529 | T>A | No | EVA | |
rs3412736671 | 532 | R>* | No | EVA | |
rs3389587021 | 545 | H>Y | No | EVA | |
rs3389583615 | 560 | S>N | No | EVA | |
rs3389533336 | 580 | L>I | No | EVA | |
rs3412942500 | 584 | H>L | No | EVA | |
rs3412642842 | 603 | E>K | No | EVA | |
rs3412806513 | 604 | L>F | No | EVA | |
rs3389592445 | 607 | S>E* | No | EVA | |
rs3411255506 | 608 | G>E | No | EVA | |
rs3389581427 | 609 | N>D | No | EVA | |
rs3389584026 | 611 | L>F | No | EVA | |
rs31637309 | 613 | R>H | No | EVA | |
rs3389576437 | 623 | W>* | No | EVA | |
rs3389576291 | 623 | W>* | No | EVA | |
rs3389562820 | 631 | N>K | No | EVA | |
rs31637306 | 651 | L>F | No | EVA | |
rs3389586923 | 659 | E>* | No | EVA | |
rs3389550891 | 691 | L>M | No | EVA | |
rs234872463 | 697 | C>Y | No | EVA | |
rs3389582644 | 710 | L>P | No | EVA | |
rs216974417 | 724 | S>P | No | EVA | |
rs252275377 | 745 | S>T | No | EVA | |
rs3389540482 | 775 | R>Q | No | EVA | |
rs3389583646 | 804 | S>N | No | EVA | |
rs214652691 | 836 | A>T | No | EVA | |
rs3389578714 | 840 | H>D | No | EVA | |
rs3389582662 | 842 | L>P | No | EVA | |
rs1133010183 | 851 | Y>D | No | EVA | |
rs3389577131 | 869 | T>A | No | EVA | |
rs251013101 | 883 | S>T | No | EVA | |
rs3389491370 | 910 | E>V | No | EVA | |
rs3389594347 | 911 | R>S | No | EVA | |
rs3402728423 | 913 | W>G | No | EVA | |
rs3389594398 | 944 | S>R | No | EVA | |
rs3389578708 | 947 | F>S | No | EVA | |
rs3389578735 | 979 | Q>H | No | EVA | |
rs3389533370 | 989 | K>M | No | EVA | |
rs3389533399 | 1030 | R>T | No | EVA |
No associated diseases with P58682
22 regional properties for P58682
Type | Name | Position | InterPro Accession |
---|---|---|---|
domain | Toll/interleukin-1 receptor homology (TIR) domain | 869 - 1016 | IPR000157 |
repeat | Leucine-rich repeat | 65 - 99 | IPR001611-1 |
repeat | Leucine-rich repeat | 271 - 318 | IPR001611-2 |
repeat | Leucine-rich repeat | 501 - 555 | IPR001611-3 |
repeat | Leucine-rich repeat | 576 - 597 | IPR001611-4 |
repeat | Leucine-rich repeat | 624 - 667 | IPR001611-5 |
repeat | Leucine-rich repeat | 704 - 725 | IPR001611-6 |
repeat | Leucine-rich repeat | 728 - 749 | IPR001611-7 |
repeat | Leucine-rich repeat, typical subtype | 66 - 85 | IPR003591-1 |
repeat | Leucine-rich repeat, typical subtype | 120 - 143 | IPR003591-2 |
repeat | Leucine-rich repeat, typical subtype | 195 - 218 | IPR003591-3 |
repeat | Leucine-rich repeat, typical subtype | 281 - 304 | IPR003591-4 |
repeat | Leucine-rich repeat, typical subtype | 305 - 329 | IPR003591-5 |
repeat | Leucine-rich repeat, typical subtype | 388 - 411 | IPR003591-6 |
repeat | Leucine-rich repeat, typical subtype | 412 - 435 | IPR003591-7 |
repeat | Leucine-rich repeat, typical subtype | 520 - 543 | IPR003591-8 |
repeat | Leucine-rich repeat, typical subtype | 574 - 597 | IPR003591-9 |
repeat | Leucine-rich repeat, typical subtype | 629 - 652 | IPR003591-10 |
repeat | Leucine-rich repeat, typical subtype | 678 - 701 | IPR003591-11 |
repeat | Leucine-rich repeat, typical subtype | 703 - 725 | IPR003591-12 |
repeat | Leucine-rich repeat, typical subtype | 727 - 749 | IPR003591-13 |
repeat | BspA-type LRR region | 355 - 423 | IPR026906 |
3 GO annotations of cellular component
Name | Definition |
---|---|
endosome membrane | The lipid bilayer surrounding an endosome. |
external side of plasma membrane | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. |
plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
4 GO annotations of molecular function
Name | Definition |
---|---|
DNA binding | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). |
double-stranded RNA binding | Binding to double-stranded RNA. |
pattern recognition receptor activity | Combining with a pathogen-associated molecular pattern (PAMP), a structure conserved among microbial species to initiate an innate immune response. |
single-stranded RNA binding | Binding to single-stranded RNA. |
16 GO annotations of biological process
Name | Definition |
---|---|
canonical NF-kappaB signal transduction | The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. |
cellular response to mechanical stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. |
defense response to virus | Reactions triggered in response to the presence of a virus that act to protect the cell or organism. |
inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
innate immune response | Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. |
negative regulation of interleukin-12 production | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-12 production. |
positive regulation of innate immune response | Any process that activates or increases the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection. |
positive regulation of interferon-alpha production | Any process that activates or increases the frequency, rate, or extent of interferon-alpha production. |
positive regulation of interferon-beta production | Any process that activates or increases the frequency, rate, or extent of interferon-beta production. |
positive regulation of interleukin-1 beta production | Any process that activates or increases the frequency, rate, or extent of interleukin-1 beta production. |
positive regulation of interleukin-6 production | Any process that activates or increases the frequency, rate, or extent of interleukin-6 production. |
positive regulation of interleukin-8 production | Any process that activates or increases the frequency, rate, or extent of interleukin-8 production. |
positive regulation of type II interferon production | Any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon. |
regulation of protein phosphorylation | Any process that modulates the frequency, rate or extent of addition of phosphate groups into an amino acid in a protein. |
toll-like receptor 8 signaling pathway | The series of molecular signals initiated by a ligand binding to the endolysosomal toll-like receptor 8. |
toll-like receptor signaling pathway | The series of molecular signals initiated by a ligand binding to a toll-like receptor of a target cell. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate an innate immune response. |
10 | 20 | 30 | 40 | 50 | 60 |
MENMPPQSWI | LTCFCLLSSG | TSAIFHKANY | SRSYPCDEIR | HNSLVIAECN | HRQLHEVPQT |
70 | 80 | 90 | 100 | 110 | 120 |
IGKYVTNIDL | SDNAITHITK | ESFQKLQNLT | KIDLNHNAKQ | QHPNENKNGM | NITEGALLSL |
130 | 140 | 150 | 160 | 170 | 180 |
RNLTVLLLED | NQLYTIPAGL | PESLKELSLI | QNNIFQVTKN | NTFGLRNLER | LYLGWNCYFK |
190 | 200 | 210 | 220 | 230 | 240 |
CNQTFKVEDG | AFKNLIHLKV | LSLSFNNLFY | VPPKLPSSLR | KLFLSNAKIM | NITQEDFKGL |
250 | 260 | 270 | 280 | 290 | 300 |
ENLTLLDLSG | NCPRCYNAPF | PCTPCKENSS | IHIHPLAFQS | LTQLLYLNLS | STSLRTIPST |
310 | 320 | 330 | 340 | 350 | 360 |
WFENLSNLKE | LHLEFNYLVQ | EIASGAFLTK | LPSLQILDLS | FNFQYKEYLQ | FINISSNFSK |
370 | 380 | 390 | 400 | 410 | 420 |
LRSLKKLHLR | GYVFRELKKK | HFEHLQSLPN | LATINLGINF | IEKIDFKAFQ | NFSKLDVIYL |
430 | 440 | 450 | 460 | 470 | 480 |
SGNRIASVLD | GTDYSSWRNR | LRKPLSTDDD | EFDPHVNFYH | STKPLIKPQC | TAYGKALDLS |
490 | 500 | 510 | 520 | 530 | 540 |
LNNIFIIGKS | QFEGFQDIAC | LNLSFNANTQ | VFNGTEFSSM | PHIKYLDLTN | NRLDFDDNNA |
550 | 560 | 570 | 580 | 590 | 600 |
FSDLHDLEVL | DLSHNAHYFS | IAGVTHRLGF | IQNLINLRVL | NLSHNGIYTL | TEESELKSIS |
610 | 620 | 630 | 640 | 650 | 660 |
LKELVFSGNR | LDRLWNANDG | KYWSIFKSLQ | NLIRLDLSYN | NLQQIPNGAF | LNLPQSLQEL |
670 | 680 | 690 | 700 | 710 | 720 |
LISGNKLRFF | NWTLLQYFPH | LHLLDLSRNE | LYFLPNCLSK | FAHSLETLLL | SHNHFSHLPS |
730 | 740 | 750 | 760 | 770 | 780 |
GFLSEARNLV | HLDLSFNTIK | MINKSSLQTK | MKTNLSILEL | HGNYFDCTCD | ISDFRSWLDE |
790 | 800 | 810 | 820 | 830 | 840 |
NLNITIPKLV | NVICSNPGDQ | KSKSIMSLDL | TTCVSDTTAA | VLFFLTFLTT | SMVMLAALVH |
850 | 860 | 870 | 880 | 890 | 900 |
HLFYWDVWFI | YHMCSAKLKG | YRTSSTSQTF | YDAYISYDTK | DASVTDWVIN | ELRYHLEESE |
910 | 920 | 930 | 940 | 950 | 960 |
DKSVLLCLEE | RDWDPGLPII | DNLMQSINQS | KKTIFVLTKK | YAKSWNFKTA | FYLALQRLMD |
970 | 980 | 990 | 1000 | 1010 | 1020 |
ENMDVIIFIL | LEPVLQYSQY | LRLRQRICKS | SILQWPNNPK | AENLFWQSLK | NVVLTENDSR |
1030 | |||||
YDDLYIDSIR | QY |